Eris Lifesciences Ltd Stock Analysis

BSE: 540596 | NSE: ERIS | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 31-Mar-2023 18:02
572.05 -2.15 (-0.37%)

DeciZen - Make an Informed Decision on Eris Lifesciences

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Eris Lifesciences Price Chart

P/E Ratio ( CD) :
Market Cap :
7,779.4 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Eris Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Eris Lifesciences Ltd is a good quality company.

2. Is Eris Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Eris Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Eris Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Eris Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Eris Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Eris Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 68.9%46.1%38.4%45.9%51.6%30.7%23.4%22.3%24.7%23.3%-
Value Creation Index

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3935095465977508569821,0741,2121,3471,566
YoY Gr. Rt. %-29.5%7.2%9.4%25.5%14.2%14.8%9.4%12.8%11.2%-
Adj EPS 4,250.74,936.66,320.39,56916.720.22121.6263029.2
YoY Gr. Rt. %-16.1%28%51.4%-99.8%20.5%4.3%2.7%20.5%15.3%-
BVPS (₹) 7,687.512,817.519,278.621,711.841.362.683.695.3115.8140.3156.4
Adj Net Profit 58.567.986.9132230277289293353408397
Cash Flow from Ops. 3889.690.1131200235223271375378-
Debt/CF from Ops. 0.100001.60.8000.1-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 14.7%12.4%11.1%11.2%
Adj EPS -42.3%12.4%12.6%15.3%
BVPS -35.927.718.821.1
Share Price - -6.4% 15.8% -19%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 75.94839.246.553.138.828.72424.623.419.7
Op. Profit Mgn % 2219.522.328.835.937.735.234.735.636.332.9
Net Profit Mgn % 14.913.415.922.330.732.529.527.329.130.225.4
Debt to Equity 000000.40.2000-
Working Cap Days 69717168771011181301361450
Cash Conv. Cycle 141081211-4-4714130

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 11.10%

Net Profit is growing at healthy rate in last 3 years 12.56%

Sales growth is good in last 4 quarters at 20.02%

Return on Equity has declined versus last 3 years average to 19.70%

Latest Financials - Eris Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 29.2 29.2
TTM Sales (₹ Cr.) 1,276 1,566
BVPS (₹.) 156.8 156.4
Reserves (₹ Cr.) 2,119 2,114
P/BV 3.65 3.65
PE 19.60 19.54
From the Market
52 Week Low / High (₹) 550.90 / 749.85
All Time Low / High (₹) 341.05 / 896.00
Market Cap (₹ Cr.) 7,779
Equity (₹ Cr.) 13.6
Face Value (₹) 1
Industry PE 36.2

Management X-Ray of Eris Lifesciences :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Eris Lifesciences

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Eris Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Eris Lifesciences on 31-Mar-2023 18:02 is : 572.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Mar-2023 18:02 the market cap of Eris Lifesciences stood at ₹ 7,779.4.
The latest PE ratio of Eris Lifesciences as of 31-Mar-2023 18:02 is 19.60.
The latest PB ratio of Eris Lifesciences as of 31-Mar-2023 18:02 is 3.65
The 52-week high of Eris Lifesciences is ₹ 749.9 and the 52-week low is ₹ 550.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Eris Lifesciences is ₹ 1,276 ( Cr.) .

About Eris Lifesciences Ltd

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.

The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

History and milestones

  • 2007: Incorporation of the company.
  • 2007: Launched “Eris” division focused on cardiology and diabetes segment.
  • 2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
  • 2009: Launched “Adura” division focused on cardiology and diabetes segment.
  • 2011: Launched “Montana” division focused on gynecology and pediatrics segment.
  • 2012: Launched “Inspira” division focused on cardiology segment.
  • 2014: Launched “Victus” division focused on anti-diabetes segment.
  • 2014: Set up Assam Facility by the company.
  • 2015: Launched “Eris 2” division focused on pain management segment.
  • 2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
  • 2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
  • 2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
  • 2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
  • 2017: Eris acquires 40 trademarks from Amay Pharma
  • 2017: Eris acquires Pune based UTH Healthcare.
  • 2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
  • 2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
  • 2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now